For how we live.
A 411,000-patient claims study found adults on GLP-1 drugs who started oxycodone had more severe constipation and bowel obstruction at 30 days than those starting hydrocodone or tramadol.
The older oral preventives managed 0.44 to 1.4. The larger change is that the new drugs work in people the old ones failed, and are tolerated well enough to stay taken.
An analysis of the FDA's voluntary reporting database finds herbal and weight-loss products carry the highest serious-outcome rate. The author is explicit that these are flags for investigation, not proven risks.
A five-year FAERS analysis found both semaglutide and tirzepatide carry disproportionate ketoacidosis signals in people without diabetes, with roughly three-quarters of reported cases requiring hospitalization.
Semaglutide showed a sixfold reporting signal for polycystic ovary syndrome and a smaller but real alopecia signal. Dulaglutide and tirzepatide showed lower or no signal for the same reproductive events.
Both drugs suppress ovarian and testicular hormone production, but two decades of FDA safety reports show leuprolide skewing toward reproductive and cancer-related signals, goserelin toward endocrine ones.
Two trials showed more deaths on voxelotor than placebo. The registry data that triggered the 2024 precautionary suspension did not confirm the original signal — the trials did something worse.